
Edgewise Therapeutics, Inc.: updates and filings
Price
$41.17
November 19, 2026Market cap $4.4B
What Ploutos Investor adds for Edgewise Therapeutics
Part of Ploutos Investor, €9.99 a month
- The full history: 6 fiscal years, from 2020
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Notes on these figures
- Earnings per share here are the last twelve months' earnings over today's shares, so they agree with the P/E. The number of shares changed a lot during the year, so they differ from the earnings per share the company filed, which use the year's average number of shares.
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
November 2026
August 2026
May 2026
February 2026
November 2025
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 16, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Nov 5, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Nov 4, 2026Results of operationsForm8-K
- Nov 4, 2026Quarterly reportfor the period to Sep 30, 2026Form10-Q
- Aug 14, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Aug 14, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Aug 14, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Aug 6, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- Aug 6, 2026Quarterly reportfor the period to Jun 30, 2026Form10-Q
- Aug 6, 2026Results of operationsForm8-K
- Jul 16, 2026Financial statements and exhibits (amendment)Form8-K/A
- Jul 13, 2026Acquisition or disposal of assets, Regulation FD disclosureForm8-K
- Jun 5, 2026Shareholder voteForm8-K
- Jun 1, 2026Material agreement enteredForm8-K
- May 15, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- May 7, 2026Shares registered for employeesFormS-8
- May 7, 2026Results of operationsForm8-K
- May 7, 2026Quarterly reportfor the period to Mar 31, 2026Form10-Q
- Apr 27, 2026Over-5% holder statement (active) (amendment)FormSCHEDULE 13D/A
- Apr 23, 2026Annual report to shareholdersfor the period to Dec 31, 2025FormARS
- Apr 23, 2026Additional annual meeting materialFormDEFA14A
- Apr 23, 2026Annual meeting proxy statementFormDEF 14A
- Feb 26, 2026Annual reportfor the period to Dec 31, 2025Form10-K
- Feb 26, 2026Results of operationsForm8-K
- Feb 17, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 16, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Nov 5, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Nov 4, 2026 | 8-K | Results of operations | Document |
| Nov 4, 2026 | 10-Q | Quarterly reportfor the period to Sep 30, 2026 | Document |
| Aug 14, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Aug 14, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Aug 14, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Aug 6, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| Aug 6, 2026 | 10-Q | Quarterly reportfor the period to Jun 30, 2026 | Document |
| Aug 6, 2026 | 8-K | Results of operations | Document |
| Jul 16, 2026 | 8-K/A | Financial statements and exhibits (amendment) | Document |
| Jul 13, 2026 | 8-K | Acquisition or disposal of assets, Regulation FD disclosure | Document |
| Jun 5, 2026 | 8-K | Shareholder vote | Document |
| Jun 1, 2026 | 8-K | Material agreement entered | Document |
| May 15, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| May 7, 2026 | S-8 | Shares registered for employees | Document |
| May 7, 2026 | 8-K | Results of operations | Document |
| May 7, 2026 | 10-Q | Quarterly reportfor the period to Mar 31, 2026 | Document |
| Apr 27, 2026 | SCHEDULE 13D/A | Over-5% holder statement (active) (amendment) | Document |
| Apr 23, 2026 | ARS | Annual report to shareholdersfor the period to Dec 31, 2025 | Document |
| Apr 23, 2026 | DEFA14A | Additional annual meeting material | Document |
| Apr 23, 2026 | DEF 14A | Annual meeting proxy statement | Document |
| Feb 26, 2026 | 10-K | Annual reportfor the period to Dec 31, 2025 | Document |
| Feb 26, 2026 | 8-K | Results of operations | Document |
| Feb 17, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Sep 26, 2019.
The full analysis
What do Edgewise Therapeutics's filings show?
The filings are where every one of Edgewise Therapeutics's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.